This trial is testing a new way to image tumors during surgery, which may help surgeons better identify and remove cancer cells.
2 Primary · 3 Secondary · Reporting Duration: up to 14 days
Experimental Treatment
36 Total Participants · 4 Treatment Groups
Primary Treatment: IRDye800CW-nimotuzumab · No Placebo Group · Phase 1 & 2
Age 18 - 80 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: